Atossa Genetics (ATOS) Competitors $0.82 -0.01 (-0.70%) Closing price 04:00 PM EasternExtended Trading$0.82 0.00 (-0.51%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. ORKA, ATAI, RAPP, RGNX, ERAS, ABVX, FULC, ITOS, BNTC, and RVNCShould you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include Oruka Therapeutics (ORKA), atai Life Sciences (ATAI), Rapport Therapeutics (RAPP), REGENXBIO (RGNX), Erasca (ERAS), Abivax (ABVX), Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Benitec Biopharma (BNTC), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry. Atossa Genetics vs. Its Competitors Oruka Therapeutics atai Life Sciences Rapport Therapeutics REGENXBIO Erasca Abivax Fulcrum Therapeutics iTeos Therapeutics Benitec Biopharma Revance Therapeutics Atossa Genetics (NASDAQ:ATOS) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Do analysts prefer ATOS or ORKA? Atossa Genetics presently has a consensus target price of $6.17, indicating a potential upside of 648.20%. Oruka Therapeutics has a consensus target price of $40.38, indicating a potential upside of 242.16%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atossa Genetics is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has better earnings and valuation, ATOS or ORKA? Atossa Genetics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$25.50M-$0.21-3.92Oruka TherapeuticsN/AN/A-$83.72M-$4.51-2.62 Which has more volatility and risk, ATOS or ORKA? Atossa Genetics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500. Does the media prefer ATOS or ORKA? In the previous week, Oruka Therapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 2 mentions for Oruka Therapeutics and 1 mentions for Atossa Genetics. Oruka Therapeutics' average media sentiment score of 1.89 beat Atossa Genetics' score of 1.87 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Atossa Genetics Very Positive Oruka Therapeutics Very Positive Is ATOS or ORKA more profitable? Oruka Therapeutics' return on equity of -25.66% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -33.90% -31.53% Oruka Therapeutics N/A -25.66%-23.39% Do institutionals and insiders believe in ATOS or ORKA? 12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 8.7% of Atossa Genetics shares are held by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryOruka Therapeutics beats Atossa Genetics on 9 of the 14 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.21M$6.78B$5.48B$8.94BDividend YieldN/A1.04%5.38%4.12%P/E Ratio-3.9227.0626.2219.73Price / SalesN/A85.89405.80109.12Price / CashN/A21.0536.4957.06Price / Book1.454.707.925.37Net Income-$25.50M$173.18M$3.15B$248.34M7 Day Performance-0.22%0.02%0.95%1.25%1 Month Performance5.06%9.70%5.25%5.41%1 Year Performance-31.32%23.50%32.63%18.06% Atossa Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics2.3435 of 5 stars$0.82-0.7%$6.17+648.2%-30.3%$107.21MN/A-3.928Positive NewsORKAOruka Therapeutics3.0309 of 5 stars$10.90-6.7%$40.38+270.4%N/A$408.10MN/A-2.42N/AATAIatai Life Sciences3.0046 of 5 stars$2.02-18.5%$8.67+329.0%+64.7%$404.69M$310K-2.2280Trending NewsOptions VolumeGap UpHigh Trading VolumeRAPPRapport Therapeutics2.28 of 5 stars$10.88-0.4%$32.67+200.2%N/A$397.12MN/A-3.15N/APositive NewsGap DownRGNXREGENXBIO4.5337 of 5 stars$7.86-6.8%$31.63+302.4%-29.8%$394.26M$83.33M-2.53370Positive NewsERASErasca2.8968 of 5 stars$1.39+1.5%$4.57+228.9%-46.2%$393.77MN/A-2.24120News CoverageABVXAbivax2.3957 of 5 stars$6.11+2.3%$31.00+407.4%-42.1%$387.68MN/A0.0061Positive NewsGap UpFULCFulcrum Therapeutics0.3348 of 5 stars$7.17+2.6%$6.29-12.3%+11.0%$387.03M$80M-102.41100ITOSiTeos Therapeutics3.1978 of 5 stars$10.11+1.5%$15.86+56.8%-32.8%$386.95M$35M-3.3390BNTCBenitec Biopharma1.6605 of 5 stars$14.57-0.3%$23.83+63.6%+67.4%$382.46M$80K-9.6520High Trading VolumeRVNCRevance Therapeutics2.7116 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies ORKA Alternatives ATAI Alternatives RAPP Alternatives RGNX Alternatives ERAS Alternatives ABVX Alternatives FULC Alternatives ITOS Alternatives BNTC Alternatives RVNC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
